DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20205087

Children with solid tumors treated in our centre

Hakan Sarbay, Mustafa Okumus, Idris Sertbas, Uguray Payam Hacisalihoglu, Avni Atay, Baris Malbora

Abstract


Background: General characteristics and responses to treatment of patients with solid tumors were investigated.

Methods: Patients treated with a diagnosis of solid tumors in the pediatric hematology and oncology clinic between March 2019 and June 2020 were included in the study. The gender, age, diagnosis, age of diagnosis, risk status, stage, treatment details, and treatment complications of the patients were evaluated. The risk status of the patients was determined according to the stage of each diagnosis, metastasis status and treatment protocol. It was noted whether the patients had undergone surgery or not, and patients who were in-operable were specified. Patients receiving radiotherapy were specified. The chemotherapeutic drugs given to the patients according to the treatment protocols were indicated one by one. Treatment complications or morbidity states were recorded.

Results: Out of the 31 patients evaluated, 10 (32%) were female and 21 (68%) were male. The mean±SD age was 6.3±5.16 years. The youngest patient was 3 months old, and the oldest patient was 18 years old. The central nervous system was the most commonly affected area and 7 (22%) of the patients had various CNS tumors. The second most common malignancy is neuroblastoma; 4 patients (12%). Rhabdomyosarcoma and retinoblastoma were the third most common malignancy with 3 patients each. Surgical resection was performed in 19 (61%) patients. Radiotherapy was applied to 13 of the patients (41%).

Conclusions: Early diagnosis and detection of the disease at low stage, complete tumor resection are important for the success of treatment.


Keywords


Solid tumors, Children, Chemotherapy, Radiotherapy, Autologous-HSCT

Full Text:

PDF

References


Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics. CA Cancer J Clin. 2014;64(2):83-103.

Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer. 3rd ed. Cancer. 2005;103:1457-67.

Kutluk MT, Yeşilipek A. Turkish National pediatric cancer registry 2002-2008, Turkish pediatric oncology group and Turkish pediatric hematology society. J Clin Oncol. 2017;31(15):10067.

Rajwanshi A, Srinivas R, Upasana G. Malignant small round cell tumors. J Cytol. 2009;26(1):1-10.

Picarsic J, Reyes-Múgica M. Phenotype and immunophe¬notype of the most common pediatric tumors. Appl Immunohistochem Mol Morphol. 2015;23(5):313-26.

Chen X, Pappo A, Dyer MA. Pediatric solid tumor genomics and developmental pliancy. Oncogene. 2015;34(41):5207-15.

Allen-Rhoades W, Whittle SB, Rainusso N. Pediatric solid tumors of ınfancy: an overview. Pediatr Rev. 2018;39(2):57-67.

Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, et al. The childhood solid tumor network: a new resource for the developmental biology and oncology research communities. Dev Biol. 2016;411(2):287-93.

Sharma N, Ahmad A, Bhat GM, Aziz SA, Lone MM, Bhat NA. A profile of pediatric solid tumors: A single institution experience in Kashmir. Indian J Med Paediatr Oncol. 2017;38:471-7.

Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB,Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091-102.

Glod J, Rahme GJ, Kaur H, H Raabe E, Hwang EI, Israel MA. Pediatric brain tumors: current knowledge and therapeutic opportunities. J Pediatr Hematol Oncol. 2016;38(4):249-60.

Gerber NU, von Hoff K, von Bueren AO, Treulieb W, Warmuth-Metz M, Pietsch T, et al. Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. J Neurooncol. 2011;102(3):459-69.

Davidoff AM, Fernandez-Pineda I, Santana VM, Shochat SJ. The role of neoadjuvant chemotherapy in children with malignant solid tumors. Semin Pediatr Surg. 2012;21(1):88-99.

Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363(14):1313-23.

Yamamoto K, Hanada R, Kikuchi A, Ichikawa M, Aihara T, Oguma E, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998;16(4):1265-9.

Shamberger RC. Pediatric renal tumors. Semin Surg Oncol. 1999;16:105-20.

Meyers RL. Tumors of the liver in children. Surg Oncol. 2007;16:195-203.

Otte JB. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev. 2010;36:360-71.

Ferrari A, Orbach D, Sultan I, Casanova M, Bisogno G. Neonatal soft tissue sarcomas. Semin Fetal Neonatal Med. 2012;17(4):231-8.

Merchant MS, Mackall CL. Current approach to pediatric soft tissue sarcomas. Oncologist. 2009;14(11):1139-53.